These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 31701169)

  • 21. Surgical salvage improves overall survival for patients with HPV-positive and HPV-negative recurrent locoregional and distant metastatic oropharyngeal cancer.
    Guo T; Qualliotine JR; Ha PK; Califano JA; Kim Y; Saunders JR; Blanco RG; D'Souza G; Zhang Z; Chung CH; Kiess A; Gourin CG; Koch W; Richmon JD; Agrawal N; Eisele DW; Fakhry C
    Cancer; 2015 Jun; 121(12):1977-84. PubMed ID: 25782027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histologic Typing in Oropharyngeal Squamous Cell Carcinoma: A 4-Year Prospective Practice Study With p16 and High-Risk HPV mRNA Testing Correlation.
    Gondim DD; Haynes W; Wang X; Chernock RD; El-Mofty SK; Lewis JS
    Am J Surg Pathol; 2016 Aug; 40(8):1117-24. PubMed ID: 27035614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
    Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
    J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. P16(INK4A) immunostaining is a strong indicator for high-risk-HPV-associated oropharyngeal carcinomas and dysplasias, but is unreliable to predict low-risk-HPV-infection in head and neck papillomas and laryngeal dysplasias.
    Mooren JJ; Gültekin SE; Straetmans JM; Haesevoets A; Peutz-Kootstra CJ; Huebbers CU; Dienes HP; Wieland U; Ramaekers FC; Kremer B; Speel EJ; Klussmann JP
    Int J Cancer; 2014 May; 134(9):2108-17. PubMed ID: 24127203
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Highlights from the 2021 ASCO and ESMO annual meetings on radiotherapy of head and neck cancer].
    Hecht M; von der Grün J; Semrau S; Müller S; Weissmann T; Gaipl US; Iro H; Fietkau R; Gostian AO
    HNO; 2022 Apr; 70(4):258-264. PubMed ID: 35294576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular subclassification determined by human papillomavirus and epidermal growth factor receptor status is associated with the prognosis of oropharyngeal squamous cell carcinoma.
    Nakano T; Yamamoto H; Nakashima T; Nishijima T; Satoh M; Hatanaka Y; Shiratsuchi H; Yasumatsu R; Toh S; Komune S; Oda Y
    Hum Pathol; 2016 Apr; 50():51-61. PubMed ID: 26997438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent advances in the understanding and management of oropharyngeal cancer.
    Hay A; Nixon IJ
    F1000Res; 2018; 7():. PubMed ID: 30228861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HPV-Positive Oropharyngeal Carcinoma: A Systematic Review of Treatment and Prognosis.
    Wang MB; Liu IY; Gornbein JA; Nguyen CT
    Otolaryngol Head Neck Surg; 2015 Nov; 153(5):758-69. PubMed ID: 26124261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer.
    Buglione M; Maddalo M; Corvò R; Pirtoli L; Paiar F; Lastrucci L; Stefanacci M; Belgioia L; Crociani M; Vecchio S; Bonomo P; Bertocci S; Borghetti P; Pasinetti N; Triggiani L; Costa L; Tonoli S; Grisanti S; Magrini SM
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):462-472. PubMed ID: 27986347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of the lymph node ratio in oropharyngeal carcinoma stratified for HPV-status.
    Jacobi C; Rauch J; Hagemann J; Lautz T; Reiter M; Baumeister P
    Eur Arch Otorhinolaryngol; 2018 Feb; 275(2):515-524. PubMed ID: 29204919
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma.
    Spreafico A; Huang SH; Xu W; Granata R; Liu CS; Waldron JN; Chen E; Ringash J; Bayley A; Chan KK; Hope AJ; Cho J; Razak AA; Hansen A; Jang R; Perez-Ordonez B; Weinreb I; Bossi P; Orlandi E; Licitra LF; Song Y; O'Sullivan B; Siu LL; Kim J
    Eur J Cancer; 2016 Nov; 67():174-182. PubMed ID: 27669504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High E6 Gene Expression Predicts for Distant Metastasis and Poor Survival in Patients With HPV-Positive Oropharyngeal Squamous Cell Carcinoma.
    Khwaja SS; Baker C; Haynes W; Spencer CR; Gay H; Thorstad W; Adkins DR; Nussenbaum B; Chernock RD; Lewis JS; Wang X
    Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1132-41. PubMed ID: 27209503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Point/Counterpoint: Do We De-escalate Treatment of HPV-Associated Oropharynx Cancer Now? And How?
    Wirth LJ; Burtness B; Nathan CO; Grégoire V; Richmon J
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():364-372. PubMed ID: 31099643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Staging and treatment of oropharyngeal cancer in the human papillomavirus era.
    Ward MJ; Mellows T; Harris S; Webb A; Patel NN; Cox HJ; Piper K; Ottensmeier CH; Thomas GJ; King EV
    Head Neck; 2015 Jul; 37(7):1002-13. PubMed ID: 24753272
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nodal response after 46 Gy of intensity-modulated radiotherapy is associated with human papillomavirus-related oropharyngeal carcinoma.
    Dronkers EAC; Koljenovic S; Verduijn GM; Baatenburg de Jong RJ; Hardillo JAU
    Laryngoscope; 2018 Oct; 128(10):2333-2340. PubMed ID: 29521420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human papillomavirus association is the most important predictor for surgically treated patients with oropharyngeal cancer.
    Wagner S; Wittekindt C; Sharma SJ; Wuerdemann N; Jüttner T; Reuschenbach M; Prigge ES; von Knebel Doeberitz M; Gattenlöhner S; Burkhardt E; Pons-Kühnemann J; Klussmann JP
    Br J Cancer; 2017 Jun; 116(12):1604-1611. PubMed ID: 28472822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toll-like receptor 5 and 7 expression may impact prognosis of HPV-positive oropharyngeal squamous cell carcinoma patients.
    Jouhi L; Mohamed H; Mäkitie A; Remes SM; Haglund C; Atula T; Hagström J
    Cancer Immunol Immunother; 2017 Dec; 66(12):1619-1629. PubMed ID: 28856441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MMP-7 expression may influence the rate of distant recurrences and disease-specific survival in HPV-positive oropharyngeal squamous cell carcinoma.
    Vento SI; Jouhi L; Mohamed H; Haglund C; Mäkitie AA; Atula T; Hagström J; Mäkinen LK
    Virchows Arch; 2018 Jun; 472(6):975-981. PubMed ID: 29721609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Human papillomavirus and squamous cell cancer of the head and neck region : Prognostic, therapeutic and prophylactic implications].
    Reuschenbach M; Wagner S; Würdemann N; Sharma SJ; Prigge ES; Sauer M; Wittig A; Wittekindt C; von Knebel Doeberitz M; Klussmann JP
    HNO; 2016 Jul; 64(7):450-9. PubMed ID: 26864190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. De-intensification of therapy in human papillomavirus associated oropharyngeal cancer: A systematic review of prospective trials.
    Patel RR; Ludmir EB; Augustyn A; Zaorsky NG; Lehrer EJ; Ryali R; Trifiletti DM; Adeberg S; Amini A; Verma V
    Oral Oncol; 2020 Apr; 103():104608. PubMed ID: 32163853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.